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Abstract. Pharmacotherapy of human hypertension is effective, safe and well-tolerated. Antihy- 
pertensive drugs are of three broad classes: diuretics, sympatholytics and vasodilators. The use of 
each class is discussed and a summary of therapeutic considerations offered for representative 
agents. Recent trends in antihypertensive therapy are identified. (Surv Ophthalmol 32: 
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Three decades of progress in the therapy of hu- 
man hypertension, fueled by a steady flow of novel 
pharmacologic agents, have established contempo- 
rary pharmacotherapy as broadly effective, safe, 
and acceptable to patients. Although the selection of 
specific regimens for individual patients remains a 
trial-and-error process, the wide range of currently 
available drugs virtually ensures that skilled clini- 
cians will be able to reduce blood pressure to desired 
levels in all patients. However, as the number of 
choices increases, so does the complexity of their 
application, and many today approach the antihy- 
pertensive pharmacopoea with trepidation. This re- 
view attempts to provide an overview of the current- 
ly available pharmaceuticals, limited to those used 
in chronic oral therapy, and a description of strate- 
gies for their use in contemporary practice. 
I. Oral Agents Marketed for 
Antihypertensive Therapy 
Available agents are summarized in Table 1. The 
following comments expand on some of the advan- 
tages and potential drawbacks of specific classes. 
A. DIURETICS 
Diuretics formed the basis of our original 
“stepped-care” therapy and continue to be the most 
widely used drugs worldwide. Despite possible dis- 
advantages related to physiological and biochemi- 
cal side-effects, it must be conceded that diuretics 
remain remarkably efficacious, affordable, and gen- 
erally well-tolerated. All the major trials assessing 
the efficacy of antihypertensive therapy in reducing 
cardiovascular morbidity and mortality have in- 
cluded a diuretic treatment limb, and no other class 
of drugs has ever been demonstrated to be superior 
to diuretics in reducing all-cause mortality. Con- 
cerns about the use of diuretics as initial therapy 
have centered about two issues: 1) the provocation 
of biochemical side-effects which may be related to 
adverse outcomes; and 2) the relatively high inci- 
dence of subjective side-effects which limit patient 
acceptance. 
Diuretic agents (thiazides, “loop” and indoline) 
lower blood pressure in hypertensive patients by 
impairing renal tubular sodium reabsorption 
through the inhibition of site-specific luminal mem- 
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TABLE 1 
Generic Name 
Oral Agents Used in AntihyPertensive Therapy 
Trade Name(s) 
(*combination Schedules: 












































B. Loop Diuretics 
Bumetamide Bumex 
I. DIURETICS 














ID 1 x 2.5-5.0 
DR 2.5-10 
MD 1 x 5-10 
ID 1 x 25 
DR 25 - 100 
MD 1 x 25-100 
ID 1 x 250 
DR 250-1000 
MD 1-2x 250-1000 
ID 1 x 25 
DR 25-100 
MD 1 x 25-100 
IDlx 1 
DR l-4 
MD lx 2-4 
ID 1 x 25 
DR 25-50 
MD 25-50 
ID 1 x 25 
DR 25-50 
MD 1-2x 25-50 
ID 1 x 25 
DR 2.5-5 
MD 1 x 2.5-5 
ID 1 x 2.5-10 
DR 2.5-10 
MD 1-2x 2.5-10 
IDlx 1 
DR l-4 
MD 1 x l-4 
ID 1 x 25 
DR 25-100 
MD l-2x 25-50 
IDlx 2 
DR 2-4 
MD lx 2-4 
ID 1 x 0.5 Group side effects: Similar to thia- 
DR l-8 zide except that these agents pro- 
Side effects are similar for the 
entire class of thiazide diuretics. 
Hypokalemia, hyperuricemia, hypo- 
magnesemia, hypercalcemia, azo- 
temia, muscle cramps, weakness, 
arrhythmias, dizziness, glucose 
intolerance, impotence. 
Hypercholesterolemia (increased to- 
tal, decreased HDL, hypertriglyc- 
eridemia. 
Hypercholesterolemia (increased 
total, decreased HDL), hyper- 
triglyceridemia 
Continued on next page 


























































MD 2x 25-100 
ID2x 20 
DR 20-480 




ID 1 x 50 
DR 50-200 
MD 1-2x 50-200 
ID 1 x 50 
DR 50-200 
MD 1-2x 50-100 
ID 2.5 
DR 2.5-5 
MD 1 x 2.5-5 
ID 2 x 0.05 
DR 0.1-1.2 




ID 2-3 x 250 
DR 100-2000 
MD 2 x 250-1000 
ID 1 X 0.1 (as reser- 
pine) 
MD 1 x 0.1-1.0 
DR O.l-1;O 
mote calciuria and lower blood 
levels of calcium. 
Group side effects: hyperkalemia, 
hypokalemia, (with Moduretic) 
hyponatremia, dyspepsia. 
Gynecomastia, mastodynia, men- 
strual irregularities, impotence. 
Gastrointestinal disturbances, mac- 
rocytic anemia. 
Hypokalemia, hyperuricemia, dys- 
pepsia. 
Sedation, dry mouth, constipation, 
postural hypotension, male impo- 
tence, urinary retention, weight 
gain, increased effect of alcohol, 
withdrawal (rebound) hyperten- 
sion. 
Same as clonidine. 
Sedation, dizziness, dry mouth, 
headache, gastro-intestinal dis- 
turbances, orthostatic hypoten- 
sion, decreased libido, positive 
Coomb’s test rarely with hemoly- 
tic anemia, fever, liver dysfunc- 
tion rarely with intrahepatic cho- 
lestasis and granulomas. 
Drowsiness, sedation, nasal conges- 
tion, nightmares, depression, 
lethargy, weakness, nausea, vom- 
iting, diarrhea, abdominal ’ 
cramps, peptic ulcer, extrapyra- 
midal side effects (Parkinson syn- 
drome) . 






drug) (mg/day) Side Effects 
B. Peripheral nervous system 




2. Post-junctional receptor blockers 






























ID 1 x 10 
(or load w/80) 
DR 10-100 
MD 1 x 25-50 
ID2x 10 
DR 20-60 






MD 1 x l-30 
ID 1 x 200-400 
DR 200-400 
MD 1 x 200-400 
ID 1 x 25-50 
DR 5&100 
MD 2 x 25-200 
ID 2 x 25-50 
DR 50-400 
MD 2 x 25-200 
IDlx40-80 
DR 40-240 






MD 2 x 20-240 
ID 1 x 80 
DR 80-480 
MD 1 x 80-480 
ID 2x 5-10 
DR 10-30 
MD 2x 5-15 
ID 2 x 100-200 
DR 200-1200 
MD 2-3 x 100-400 
Postural hypotension, failure of 
ejaculation, impotence, diarrhea, 
muscular weakness, nasal stufft- 
ness, bradycardia, weight gain, 
congestive heart failure. 
Same as guanadrel. 
Nasal congestion, postural hypoten- 
sion, tachycardia, inhibition of 
ejaculation, mental clouding and 
drowsiness. 
Orthostatic hypotension (first dose 
effect), headache, drowsiness, 
weakness, palpitations, dry 
mouth, nasal congestion. 
Same as prazosin. 
Group side effects: nausea, vomit- 
ing, anorexia, dizziness-bradycar- 
dia (less pronounced under beta- 
blockers with intrinsic, 
sympathomimetic activity). Con- 
fusion, vivid dreams, nightmares, 
insomnia, depression. 
Aggravation of existing impairment 
of myocardial contractility or of 
conduction through AV node. 
Respiratory distress or asthmatic 
attacks in patients with chronic 
bronchitis, emphysema, and 
asthma through blockade of 
bronchial beta, blockers, 
probably less pronounced under 
beta blockers with intrinsic sym- 
pathomimetic activity). Hypogly- 
cemia (blockade of glycy- 
genolytic and lipolytic action of 
catecholamines). Peripheral arte- 
rial insufficiency, intermittent 
claudication, Raynaud’s phenom- 
enon (through blockade of vaso- 
dilator beta,-receptors). Exacer- 
bation of coronary insufficiency 
after abrupt withdrawal of beta- 
blocker treatment in patients 
with coronary heart disease. 
Postural hypotension, dizziness, 
gastrointestinal symptoms, bron- 
chqconstriction, depression, leth- 
argy, headache. 
Continued on next page 








(mgjday) Side Effects 
III. VASODILATORS 
A. Vascular smooth muscle relaxants 
Hydralazine Apresoline IDZx 25 Palpitations, tachycardia, head- 
Apresazide* DR 50-300 aches, edema. 
Hydrap-Es* MD 2-3 x 25-100 
Ser-Ap-Es* 
Unipres* 
Minoxidil Loniten ID 2 x 2.5 Hirsutism, fluid retention, palpita- 
DR 2.5-40 tions, tachycardia. 
MD 2x 2.5-20 
B. Angiotensin converting enzyme inhibitors 
Captopril Capoten ID 2x 12.5 Dysgeusia, rash, leukopenia, pro- 
Capozide DR 25-300 teinuria, hypotension, cough. 
MD 2-3 x 12.5-100 
Enalapril Vasotec IDlx 5 Hypotension, cough. 
DR 5-40 
MD lx 5-40 
C. Calcium entry blockers 
Diltiazem Cardizem ID2x 30 Palpitations, heart block, constipa- 
DR 60-360 tion, edema. 
MD 2-3 x 30-120 
Nifedipine Procardia ID2x 10 Headaches, flushing, hypotension, 
DR 20-180 palpitations, edema. 
MD 2-3 x l&60 
Verapamil Calan ID2x 80 Heart block, constipation, head- 
Isoptin DR 160-480 aches, edema. 
MD 2-3 x 80-160 
Calan SR ID 1 x 120 
Isoptin SR DR 120-480 
MD lx 120-480 
SID: initial dosage. DR: dosage range. MD: maintenance dosage. 
brane transport systems. Regardless of their site of 
action along the nephron (the early distal tubule for 
thiazides, and the thick ascending limb of Henle’s 
loop for “loop” diuretics), diuretics lower blood 
pressure because of the sodium loss which they pro- 
duce. During the initiation of chronic diuretic ther- 
apy, negative sodium balance is induced, leading to 
a contraction of plasma and extracellular fluid vol- 
umes and a drop in cardiac output. Subsequently, 
blood volume returns toward normal and cardiac 
output rises, coincident with a fall in peripheral re- 
sistance. This “resetting” of the peripheral resis- 
tance-cardiac output relationship is unexplained 
but has been attributed to: (1) a decrease in vascu- 
lar reactivity to pressor stimuli; (2) suppression of 
endogenous circulating natriuretic agents with 
vasoconstrictor properties; or (3) to relief of “water- 
logging” of the vascular wall. 
As a consequence of the metabolic adjustments 
initiated by the natriuresis, certain biochemical ab- 
normalities reliably follow effective thiazide or loop 
diuretic therapy - kaliuresis, which may cause hy- 
pokalemia, and diminished uric acid clearance, 
which may cause hyperuricemia and gout. In addi- 
tion, through mechanisms less clearly linked to na- 
triuresis, diuretics may impair glucose tolerance 
and promote dyslipidemias. Combinations of thia- 
zides and potassium-sparing agents are now widely 
used and seem to be largely effective in preventing 
hypokalemia, although such preparations are not 
without their own side-effects. The potassium-spar- 
ing diuretic, amiloride (Midamora), when com- 
bined in a fixed dose with hydrochlorothiazide 
(Moduretic@), can cause hyponatremia, hyperuri- 
cemia and, occasionally, hypokalemia. Combina- 
tions of triamterene and hydrochlorothiazide (Dya- 
zide@, Maxzidem) share similar problems. Neither 
potassium-sparing agent seems to be of benefit in 
reversing the changes in serum cholesterol concen- 
tration induced by thiazides, but glucose tolerance 
may be improved, possibly because hypokalemia 
may be an important link between diuretic therapy 
and hyperglycemia. 
A drug structurally similar to both the thiazide 
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diuretics and the nondiuretic vasodilator, diazoxide 
(Hyperstata), the indoline derivative indapamide 
(Lozol@) is reported to have a unique combination 
of both diuretic and vasodilator properties, al- 
though as noted above, this combination of effects is 
actually shared with other chronic diuretic ther- 
apies. Like the thiazides, the onset of the antihyper- 
tensive action of indapamide is slow (weeks to 
months), but indapamide may produce less hypoka- 
lemia, hyperuricemia and hypercholesterolemia 
than thiazides in equieffective antihypertensive 
doses. 
Nor surprisingly, dietary sodium restriction is 
also capable of lowering blood pressure in patients 
with hypertension. Reducing sodium intake to ap- 
proximately 100 mEq per day (4-6 grams of NaCl/ 
day) lowers blood pressure significantly in approxi- 
mately 50% of subjects with mild hypertension. Salt 
restriction also potentiates the antihypertensive ef- 
fect of diuretic agents and is, in general, a useful 
adjunct to pharmacotherapy of hypertension. 
B. SYMPATHOLYTIC AGENTS 
Available agents are best subclassified according 
to their primary site of action, central or peripheral. 
1. Centrally active agents 
Centrally active sympatholytics lower blood pres- 
sure by inhibiting sympathetic outflow from the 
brain. Although central activity may contribute to 
the antihypertensive action of several drug classes, 
e.g., the lipid-soluble P-blocker propranolol, drugs 
with primary central activity include those that de- 
plete catecholamines, reserpine and the related 
rauwolfia alkaloids, and those with adrenergic 
agonist properties at the cr,-receptor subtype;alpha- 
methylnorepinephrine (derived from the prodrug 
alphamethyldopa [AldomeF]), clonidine (Cata- 
pres@) and guanabenz (Wytensin@). 
Reserpine, although still surprisingly widely em- 
ployed, primarily in fixed-dose combinations with 
diuretics and/or vasodilators, e.g., Ser-Ap-Es@, can 
produce profound mental depression by virtue of its 
widespread effects on central catecholaminergic sys- 
tems and is thus probably inferior to the more spe- 
cific central a,-agonists. Alphamethyldopa’s (Aldo- 
met@) central antihypertensive effect, originally 
attributed to the production of an inactive “false 
neurotransmitter” that substituted for endogenous 
catecholamines and decreased the effectiveness of 
neuronal discharge, now is known to result from the 
action of a primary metabolite, alphamethylnor- 
epinephrine (produced by the sequential actions of 
dopa-decarboxylase and dopamine P-hydroxylase 
on the substrate a-methyldopa). Alphamethylnor- 
epinephrine is a potent and quite specific agonist at 
cw,-receptors, an activity shared with the other cen- 
tral sympatholytics, clonidine and guanabenz. 
Stimulation of central a,-receptors by any of these 
agents results in an inhibition of central sympathet- 
ic discharge and produces a fall in peripheral vascu- 
lar resistance and blood pressure. However, at the 
same time, a2 stimulation may precipitate somno- 
lence, dry mouth and dizziness. Both the desired 
blood pressure lowering action and the unwanted 
side-effe?ts are due to stimulation of the same recep- 
tor subtype, but there may be differences in the 
susceptibility to each effect that may be exploited by 
the use of a recently-introduced transdermal con- 
trolled-release preparation of clonidine (Catapres 
TTS@). 
2. Peripherally Active Agents 
Peripherally active sympatholytics include the 
neuronal blockers (guanethidine [ Ismelin@] , guan- 
adrel [Hylorel@], the &blockers, cy-blockers and a 
combined CY- and &receptor blocker, labetalol 
(Normodyne@, Trandatea). 
Guanethidine and guanadrel initially inhibit the 
release of norepinephrine from peripheral sympa- 
thetic nerves and subsequently disrupt granular 
storage of catecholamines, resulting in neurotrans- 
mitter depletion. Since the drugs do not penetrate 
the central nervous system, sedation and depression 
are not problems with the neuronal blockers, but, 
unfortunately, other disturbing effects attributable 
to widespread suppression of sympathetic function 
limit patient acceptance of these agents. Orthostatic 
hypotension, frequently manifested by faintness, is 
characteristic because guanethidine and guanadrel 
inhibit the reflex neurogenic cardiovascular com- 
pensations to upright posture, and gastrointestinal 
dysfunctions, including diarrhea and constipation, 
and genitourinary effects, particularly ejaculatory 
incompetence and renal fluid retention occur with 
moderate frequency. 
Of the adrenergic receptor blockers, theJ-blockers 
have enjoyed the most popularity as antihyper- 
tensives. Seven P-blockers are currently marketed 
in the U.S. (Table I), and although there are sub- 
stantial pharmacokinetic and pharmacodynamic 
differences, all are equally effective antihyperten- 
sives. Pharmacological differences include three 
clinically relevant considerations: cardioselectivity, 
intrinsic sympathomimetic activity (ISA) and water 
solubility. 
Cardioselectivity refers to the relative P-blocking 
potency of a drug at /3,- and &-receptor subtypes. 
Since the heart is largely or exclusively populated by 
P,-receptors while other sites such as bronchial and 
vascular smooth muscle have predominantly P,-re- 
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ceptors, drugs which exhibit greater relative activity 
at p, than at & sites are termed cardioselective. The 
rationale for the development of &selective drugs 
was to diminish those unwanted side-effects (bron- 
choconstriction, peripheral vascular constriction) 
mediated by &-receptor blockade, since the antihy- 
pertensive action of the drugs seems to result from 
&-blockade. It should be recognized that cardiose- 
lectivity is only a relative selectivity; that is, given a 
high enough concentration of drug at either /3-re- 
ceptor subtype, blockade will occur. Clinically, the 
degree of cardioselectivity of the agents available is 
sufficient to offer a useful degree of differential P,- 
and &-blockade that permits the clinician to ame- 
liorate &-mediated side&effects in a substantial pro- 
portion of patients with troubling complaints of 
mild wheezing, cough, or cold extremities. 
ISA is the pharmacologic property of partial 
agonist activity and in current clinical usage refers 
to drugs having activity at the &-receptor subtype. 
Since &-receptor antagonists are often structurally 
quite similar to &-receptor agonists, it has been 
possible to produce agents which, while competi- 
tively antagonizing the effects of endogenous circu- 
lating or neuronally released catecholamines, mild- 
ly stimulate the receptors they occupy. The net 
physiologic effect of these drugs thus depends on the 
prevailing level of P-adrenergic tone and the 
strength of the partial agonist potency of the drug. 
In states of high prevailing tone, such as congestive 
heart failure or dynamic exercise, P-blocking effects 
(cardioselective or nonselective, depending on the 
agent) are prominent, and heart rate and cardiac 
output are lowered. In states of low sympathetic 
tone, e.g., resting in the supine posture, administra- 
tion of an agent with ISA may increase heart rate as 
the partial agonist property is expressed in the ab- 
sence of endogenous P-adrenergic tone. In general, 
drugs with ISA support the basal heart rate above 
that seen with non-ISA &blockers and therefore 
may be useful in selected patients who develop 
symptomatic bradycardias on non-ISA &blockers. 
In addition, P-blockers with ISA seem to cause few- 
er disturbances in lipid metabolism than those with- 
out ISA. 
The degree of lipid- or water-solubility of a com- 
pound largely dictates its route of elimination from 
the body and thus has a major impact on pharmaco- 
kinetics. Highly lipid-soluble agents are largely me- 
tabolized in the liver where biotransformation ren- 
ders them more water-soluble and facilitates renal 
and biliary excretion. Since individuals may have 
widely different hepatic drug metabolizing capaci- 
ties, plasma levels of highly lipid soluble compounds 
often vary greatly (20-fold) and unpredictably, ne- 
cessitating dose titration to ensure adequate p- 
blockade. Since the liver is a very efficient drug 
metabolizing system, lipid-soluble compounds are 
generally cleared from the circulation rapidly and 
consequently have short plasma half-lives. Con- 
versely, renal excretion of drugs is relatively slow 
and half-lives for water-soluble compounds accord- 
ingly long, Although the antihypertensive effects of 
@blockers are not strictly dependent on mainte- 
nance of &blocking plasma concentrations, in gen- 
eral, the longer the plasma half-life, the longer the 
dosing interval, Thus, the most water-soluble 
agents (nadolol [Corgard*], atenolol [Tenormin”], 
acebutalol [SectraP]) can be dosed once daily while 
highly lipid-soluble drugs (propranolol [InderaP]) 
require multiple daily (24 times per day) dosing. 
Recently, a sustained-release propranolol prepara- 
tion (Inderal LA@) has been introduced to allow 
once daily dosing of that drug. 
Currently available agents permit selection of the 
various combinations of cardioselectivity, ISA and 
water solubility for particular patient needs. It 
should be reemphasized that such tailoring of ther- 
apy is directed solely toward avoiding side effects 
and increasing compliance, as all the available /3- 
blockers have equivalent antihypertensive potency. 
When a P-blocker is selected as an antihypertensive 
to take advantage of a related activity, e.g., cardio- 
protection in the post-myocardial infarction patient, 
pharmacological differences must be considered, as 
not all P-blockers manifest the same activity for 
these non-hypertension indications. 
Alpha-blocking agents such as phenoxybenzamine 
(Dibenzylinea) have been available for many years, 
but were of limited utility because they produced 
unacceptable physiological side-effects (tachycar- 
dia, palpitations, dizziness). These effects resulted 
from nonselective a-blockade at both cy, and cyZ sites 
and are less prominent with the available a,-selec- 
tive agents, prazosin (Minipresm) and terazosin 
(Hytrina). Selective cr,-blockade antagonizes the ef- 
fect of circulating or neuronally-released catechola- 
mines at vascular a,-receptors without antagonizing 
the effect of catecholamines on a,-receptors located 
on the prejunctional membranes of peripheral sym- 
pathetic nerve endings. Stimulation of these c+re- 
ceptors decreases neurotransmitter output during 
subsequent nerve discharges, a form of negative 
feedback control. At sites innervated by sympathet- 
ic nerves, but not controlled by postjunctional cy,- 
receptors, such as the heart with its postjunctional 
P,-receptors, normal feedback inhibition by a;-re- 
ceptor activation seems to be effective in controlling 
the reflex sympathetic activation resulting from the 
blood pressure-lowering effect of vascular cr,-block- 
ade. Thus, prazosin causes vasodilation without 
prominent reflex tachycardia. The degree of blood 
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pressure lowering resulting from the administration 
of prazosin is dependent upon the level of cr-adren- 
ergic tone at the blood vessels, and particularly 
when such tone is high, as in the sodium-depleted 
state, profound hypotension may result from the 
first dose of prazosin. This hypotensive effect, which 
may be unpredictable, does not routinely occur with 
subsequent doses, as the cardiovascular system 
seems to shift to nonadrenergic mechanisms to sup- 
port blood pressure. 
A single agent with both CY,- and nonselective P- 
blocking properties, labetalol, combines the physio- 
logical profiles of the two classes. Like other cyI- 
blockers, labetalol lowers blood pressure acutely by 
vasodilation while its &blocking properties blunt 
the tendency to reflex sympathetic stimulation of 
the heart. The net result is maintenance of cardiac 
output and heart rate during labelatol therapy, 
making the drug useful in selected patients intoler- 
ant of the negative chronotrophic and inotrophic 
cardiac effects of other &blockers. In addition, la- 
beta101 has been demonstrated to be of benefit in 
lowering blood pressure in certain groups, such as 
black hypertensives, with relative resistance to the 
antihypertensive effects of other P-blockers. The 
main limitations of labetalol seem to be a fairly high 
incidence of side-effects, notably dizziness and gas- 
trointestinal disturbances, the former being particu- 
larly common in diuretic-treated patients. 
5. Vasodilators 
Because the hemodynamic lesion of essential hy- 
pertension is increased vascular resistance, vasodi- 
lation is an attractive antihypertensive mechanism. 
However, as with the nonselective o-blockers, the 
physiologic adjustments provoked by early attempts 
at vasodilator monotherapy proved to be limiting. 
Palpitations, tachycardia, stimulation of renin and 
catecholamine secretion, renal salt and water reten- 
tion and headaches were common side effects of 
monotherapy with hydralazine (Apresoline@). Va- 
sodilators were therefore relegated to “Step 3” ther- 
apy, where they were applied in combination with 
diuretic and sympatholytic drugs to prevent the ex- 
pression of the reflex adjustments to vasodilation. In 
addition to hydralazine, minoxidil (Loniten@), the 
most potent oral direct vasodilator available, found 
use as a third agent in hypertension refractory to 
diuretic plus sympatholytic therapy, although the 
unexpected provocation of hirsutism by minoxidil 
limited its acceptance, particularly among women. 
Recently, however, new vasodilator-type drugs, the 
angiotensin-converting-enzyme inhibitors and the 
calcium-entry blockers, have been gaining popular- 
ity both as monotherapies and in combination with 
diuretic or sympatholytic drugs. 
Angiotensin converting enzyme (ACE) inhibitors 
competitively antagonize the carboxypeptidase en- 
zyme responsible for the cleavage of inactive angio- 
tensin I (itself the cleavage product of the action of 
renin on renin substrate) to angiotensin II. Angio- 
tensin II is active at specific surface-membrane- 
bound receptor sites mediating vascular smooth 
muscle contraction, aldosterone secretion, thirst, 
and salt retention. Although the precise contribu- 
tion of each action of angiotensin II to the mainte- 
nance of hypertension is unclear, blockade of angio- 
tensin II production by ACE1 effectively lowers 
blood pressure by reducing vascular resistance. Re- 
flex sympathetic activation is minimal, and in most 
hypertensives, neither heart rate nor cardiac output 
is significantly affected by ACE inhibitors, Possible 
explanations of this blunting of the expected sympa- 
thetic response to vasodilation include increased va- 
gal discharge and a “desensitizing” effect of ACE 
inhibitors at peripheral nerve endings. At present, 
the precise nature of the interaction of ACE inhibi- 
tors and the sympathetic nervous system is incom- 
pletely understood, but the drugs are clearly effec- 
tive and well-tolerated vasodilators. 
Two ACE inhibitors are currently available, cap- 
topril (Capote@‘) and enalapril (Vasotec@). Both 
are effective inhibitors of ACE, and the drugs differ 
only in pharmacokinetic properties and side-effects. 
Captopril was the first oral ACE inhibitor released 
in the United States, and was initially regarded as 
having most promise in severe, resistant hyperten- 
sives where it was used in rather high doses (>300 
mg) in patients refractory to other agents. Early 
reports of granulocytopenia and proteinuria associ- 
ated with captopril limited physician acceptance of 
the agent, particularly in patients with mild-to- 
moderate hypertension for whom good therapeutic 
alternatives existed. Subsequent experience has 
demonstrated captopril to be generally free of seri- 
ous side-effects when used at lower doses in subjects 
free of renal failure, which impairs captopril excre- 
tion, and collagen vascular disease, a host factor 
which seems to predispose patients to granulocyto- 
penia. The observation that suppression of white 
cell production and the development of proteinuria 
seem to be similar to effects attributed to a structur- 
ally related compound, penicillamine, led to modift- 
cations of the structure of captopril to remove a free 
sulphydryl group at one end of the molecule. The 
first non-sulphydryl ACE inhibitor, enalapril, was 
recently introduced and has proven to be almost free 
of penicillamine-like side effects. It should be em- 
phasized that many of the serious adverse effects 
attributed to captopril in earlier studies were prob- 
ably related to the high doses of captopril employed, 
and such effects are rare in the lower dose range 
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currently recommended (Table 1). Captopril does 
produce several minor side-effects such as dysgeusia 
and rash that also may be less frequently seen with 
enalapril. Those side effects related to inhibition of 
angiotensin II production (hypotension, flushing, 
hyperkalemia) or to decreased bradykinin destruc- 
tion (cough) are shared by both drugs. 
Apart from side effects, the only notable differ- 
ence between captopril and enalapril is in duration 
of action. Captopril has a plasma half-life of ap- 
proximately two hours and is generally dosed twice 
daily, although recent studies suggest that some pa- 
tients may be adequately controlled on once daily 
dosing. Enalapril is an inactive prodrug, which is 
converted in the liver to an active metabolite, enala- 
prilat. Enalaprilat has a half-life of 6-35 hours and 
therefore is effective when dosed once daily. Both 
captopril and enalaprilat are primarily renally ex- 
creted and require dosage adjustments in patients 
with renal insufficiency. 
ACE inhibition has provoked considerable inter- 
est as an initial monotherapy for uncomplicated 
mild-to-moderate hypertension. The ACE inhibi- 
tors seem to be comparable in efficacy to the most 
widely used alternative therapies, diuretics and /3- 
blockers, and have an apparent advantage in terms 
of side effects. As noted above, concerns have been 
raised about the metabolic side effects of diuretics 
and @-blockers, and ACE inhibitors do not cause 
hypokalemia or have significant effects on lipid me- 
tabolism. Perhaps most importantly, they do not 
produce central nervous system disturbances and 
generally are better tolerated than sympatholytic 
therapies. A major difficulty in justifying substitu- 
tion of ACE inhibitors for diuretics or P-blockers as 
initial therapy is our lack of longterm efficacy expe- 
rience, particularly as regards outcomes related to 
cardio- and cerebrovascular events. 
The calcium entry blockers are a chemically di- 
verse group of compounds that share the ability to 
block the influx of calcium across cell membranes. 
Initially developed as antiarrhythmic, antianginal 
agents, the three calcium entry blockers currently 
available, verapamil @optin@, Calan@), nifedipine 
(Procardiaa) and diltiazem (Cardizem@), all have 
significant and roughly equivalent antihypertensive 
effects. Differential sensitivity of target tissues to 
each drug results in differing hemodynamic profiles. 
Verapamil has substantial negative chronotropic 
and inotropic effects with relatively little vasodilat- 
ing potency while nifedipine is a potent vascular 
smooth muscle dilator with little direct effect on 
cardiac tissue, and diltiazem has mixed actions at 
both cardiac and vascular sites. The net effect of all 
three drugs is to lower blood pressure. Relative tis- 
sue specificities are also important determinants of 
side-effects. Verapamil can precipitate cardiac con- 
duction system disturbances and congestive heart 
failure, while nifedipine may cause headaches, 
flushing and, via reflex activation of the sympathetic 
nervous system, palpitations and tachycardia suffi- 
cient to provoke angina. Diltiazem, with its more 
balanced actions, produces less dramatic side ef- 
fects, but can slow heart rate and conduction veloc- 
ity. Because calcium influx is important to the func- 
tion of many noncardiovascular organs, other side 
effects, particularly constipation with verapamil, 
may be limiting in some patients. Many patients 
develop edema in the absence of signs or symptoms 
of congestive heart failure, perhaps because of a 
“capillary leak” induced by calcium entry blockers. 
Contributing to the antihypertensive effects pro- 
duced by effects of calcium entry blockers on blood 
vessels and the heart may be their ability to promote 
natriuresis while lowering blood pressure. This na- 
triuretic property is in marked contrast to the anti- 
natriuretic effect of most other vasodilators and may 
be related to either renal vasodilation or to a tubular 
action of calcium entry blockers. All three calcium 
entry blockers require two to three daily doses to 
achieve smooth blood pressure control. The recent 
introduction of sustained release preparations of 
verapamil (Isoptin-SR @, Calan-SR@) now permits 
once-daily dosing. 
II. Recent Trends in Antihypertensive 
Therapy 
The goal of antihypertensive therapy continues to 
be to lower the blood pressure. The rationale for this 
approach is the considerable evidence demonstrat- 
ing reductions in fatal and nonfatal cardiovascular 
events when blood pressure is lowered with drugs, 
and it is supposed that spontaneous or nonpharma- 
cologically induced reductions are of similar benefit. 
Current concerns relate less to whether to lower blood 
pressure than to how to lower it. Although benefits 
are already substantial, can we do better for our 
patients? 
The landmark Veterans’ Administration Cooper- 
ative Trial established a standardized therapeutic 
strategy, stepped care, for the management of all 
hypertensives. Stepped care is initiated with diuret- 
ic monotherapy, and in patients failing to come 
under adequate control, a sympatholytic drug is 
added, therapy progressing to a three-drug combi- 
nation with the addition of a vasodilator in very 
resistant patients. Not only have recent drug devel- 
opments (ACE inhibitors, calcium entry blockers) 
somewhat blurred these traditional steps, but the 
entire strategy is now being questioned. With the 
emergence of effective monotherapeutic alternatives 
to diuretics, nonresponders to a drug can be with- 
CONTEMPORARY ANTIHYPERTENSIVE THERAPY 
drawn from therapy and given an agent from an- 
other class with a reasonable expectation of success. 
Unfortunately, specific tailoring of drug mechanism 
to pathophysiologic abnormality is not yet possible, 
but monotherapy is the norm for most mild-to-mod- 
erate hypertensives. Whether one drug is superior to 
another as monotherapy is currently hotly debated, 
although direct comparative trials are rare. 
Various factors other than efficacy need to be 
considered in the selection of drugs for control of 
hypertension, the main ones being symptomatic 
side effects; biochemical side effects; convenience; 
and expense of administration. The quality of life of 
the patient taking medication is the most important 
of these. Given comparable efficacy, those antihy- 
pertensives which produce the least side effects are 
to be preferred. The same is true of biochemical side 
effects: agents which do not alter plasma lipids, se- 
rum potassium, plasma glucose or uric acid have an 
added advantage. Once-daily dosage and low cost 
are additional reasons for favoring one drug over 
another. 
A major puzzle is the lack of evidence that drug 
therapy of hypertension decreases the incidence of 
coronary heart disease (CHD). Although epidemi- 
ologic studies amply document the fact that hyper- 
tension is a potent risk factor for CHD, most clinical 
trials of the value of antihypertensive drug therapy 
document only decreased morbidity and mortality 
from stroke with little or no benefit for CHD. This is 
a major problem, since CHD is by far the most 
common complication of mild hypertension, and an 
extremely serious one at that. Although the lack of 
efficacy against CHD is unexplained, and the possi- 
bility exists that positive results would have been 
observed if the trials had been longer or the treat- 
ment more aggressive, there is a persistent concern 
that beneficial effects of blood pressure reduction 
may have been nullified by noxious effects of drug 
therapy such as atherogenic dyslipidemia or hypo- 
kalemia. It should be emphasized that these con- 
cerns are purely speculative and not firmly enough 
grounded to warrant extrapolation to clinical prac- 
tice. In fact the results of the only large, well-de- 
signed trial comparing one class of agents (diuret- 
ics) to another (P-blockers) reveal no difference in 
total cardiovascular complications for the two dif- 
ferent treatments: patients treated with &blockers 
had somewhat fewer CHD events, but more strokes 
than those treated with diuretics. The net effect, 
then, was the same for both pharmacologic inter- 
ventions. 
A prudent approach to the management of hyper- 
tension today should include a clear emphasis on 
nonpharmacologic therapy and the control of CHD 
risk factors other than elevated blood pressure. The 
major considerations in pharmacologic manage- 
ment should be efficacy and tolerability; therefore 
drug therapy must be individualized: the ideal 
treatment is one that lowers the blood pressure 
while not interfering with the quality of life of the 
patient. 
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